{"id":"W4378619580","doi":"10.3390/medicina59061041","title":"Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection","year":2023,"lang":"en","type":"review","venue":"Medicina","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Human immunodeficiency virus (HIV); Drug resistance; Rilpivirine; Multiple drug resistance; Virology; Pharmacology; Antiretroviral therapy; Viral load; Biology; Microbiology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008123562,0.0006582804,0.001783098,0.0003363061,0.0003130681,0.00001433855,0.0001980017,0.0002386955,0.00002339184],"category_scores_gemma":[0.0001792103,0.0002480237,0.0003680914,0.0006745466,0.0002944127,0.00002982275,0.00005590864,0.0003007588,0.00006023149],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006770271,"about_ca_system_score_gemma":0.0004729055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008846078,"about_ca_topic_score_gemma":0.0006656335,"domain_scores_codex":[0.9968907,0.0001562829,0.001403912,0.0005519324,0.0005706892,0.0004264334],"domain_scores_gemma":[0.9968111,0.001610497,0.0007336596,0.0006370316,0.0001125236,0.00009519223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001576472,0.008802777,0.0109445,0.06664894,0.01735533,0.0004509833,0.07387572,0.00001203129,0.00002532999,0.003334928,0.0465183,0.7704547],"study_design_scores_gemma":[0.00409709,0.000496308,0.00279408,0.01968218,0.002497988,0.0000177057,0.0003831048,0.0000443974,0.0002754554,0.00001800626,0.969434,0.0002597246],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.007957795,0.9692139,0.000009623776,0.008546517,0.0007630709,0.01296974,0.00011603,0.00009291514,0.0003303898],"genre_scores_gemma":[0.003747626,0.9788349,0.00008819722,0.00003309007,0.0001419606,0.001817163,0.0002830465,0.00009957939,0.01495446],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9229156,"threshold_uncertainty_score":0.9999972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06026421496698506,"score_gpt":0.3044588700438364,"score_spread":0.2441946550768513,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}